King Luther Capital Management Corp Invests $5.58 Million in Cellebrite DI Ltd. $CLBT

King Luther Capital Management Corp acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 301,239 shares of the company’s stock, valued at approximately $5,582,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Y.D. More Investments Ltd raised its stake in Cellebrite DI by 76.2% during the 2nd quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock worth $7,065,000 after buying an additional 191,020 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Cellebrite DI by 40.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after purchasing an additional 103,568 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Cellebrite DI in the 2nd quarter valued at approximately $657,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Cellebrite DI during the 3rd quarter worth approximately $19,457,000. Finally, Moody National Bank Trust Division bought a new position in Cellebrite DI in the third quarter valued at approximately $2,670,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 1.9%

NASDAQ:CLBT opened at $13.78 on Friday. The stock has a market capitalization of $3.30 billion, a PE ratio of 44.45, a P/E/G ratio of 2.15 and a beta of 1.28. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $20.86. The firm has a fifty day simple moving average of $16.71 and a 200 day simple moving average of $16.99.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, meeting analysts’ consensus estimates of $0.14. The firm had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 earnings per share. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Lake Street Capital upped their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC cut their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.